Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-β-activated Kinase 1-dependent Signaling.

Tian LanShuo JiangJing ZhangQiqing WengYang YuHaonan LiSong TianXin DingSha HuYiqi YangWeixuan WangLexun WangDuosheng LuoXue XiaoShenghua PiaoQing ZhuXianglu RongJiao Guo

Published in: Hepatology (Baltimore, Md.) (2021)

Breviscapine prevents metabolic stress-induced NASH progression through direct inhibition of TAK1 signaling. Breviscapine might be a novel therapeutic candidate for the treatment of NASH.

Keyphrases

stress induced
signaling pathway
protein kinase
combination therapy
tyrosine kinase